fda label semaglutide naion warning 2025 use linked with increased risk for in patients with diabetes KS and MO Ozempic Lawsuit
Description
Nordisk, N., Bagsvaerd, D.-M
Understanding these differences is essential for accurate patient education and appropriate therapeutic expectations
As part of this the Department of Health is issuing communications about the status of our shortages, and the appropriate and responsible use of our medicines to healthcare professionals. The company said the shortage was due to unprecedented levels of demand
Similarly, Wegovy, initially known for its weight loss effects, was approved in August 2025 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
Because these medications target entirely separate neurological pathways, they do not compete for metabolic processing or receptor binding
